{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/633b04c7409ce700112879d8/6450f5c4f7ec390011167eca?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"DMT as a stroke treatment?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/633b04c7409ce700112879d8/1668435871237-c8096c80a14f889bd8e8cdc2d10df829.jpeg?height=200","description":"<p><em>DMT (N.N-Dimethyltryptamine) is a hallucinogenic tryptamine drug which naturally occurs in plant species such as Psychotria viridis or Chacruna. It can also be made in a laboratory.</em></p><p><br></p><p>We speak with Algernon Pharmaceuticals CEO, Christopher J. Moreau, on how they are trialling DMT as a treatment for stroke.</p>","author_name":"SR Times"}